ReviewCancers2021
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 337 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
337 citing papers in PubMed, 2 syntheses or guidelines pooled it, 528 citations in OpenAlex.
- Association of EGFR and EGF gene polymorphisms with cervical cancer in a case-control study and cross-cancer meta-analysis.Scientific reports · 2026Pooled it
- Risk factors for brain metastasis in lung cancer: an umbrella review of systematic reviews and meta-analyses.BMJ open · 2025Pooled it
- Trial
- Loss of EGFR activity in skeletal stem/progenitor cells is associated with impaired fracture healing in aged mice.Bioactive materials · 2027Article
- Nrf2 and PGC-1α signaling in temozolomide resistance in glioblastoma under hypoxia.Biomedical reports · 2026Article
- Perspectives of EGFR co-targeting with nanocarriers for anti-TNBC purposes.Genes & diseases · 2026Review
- Design, synthesis, and preliminary anticancer evaluation of diphenylpropan-1-one derivatives:RSC advances · 2026Article
- Developing neoantigen cancer vaccines: where are we now?Nature communications · 2026Review
- Patient-Derived Organoids as a Model to Understand Tumor Microenvironment-Driven Nano-Bio Interactions - A Framework Towards Improved Nanomedicine Translation.bioRxiv : the preprint server for biology · 2026Article
- A nomogram prediction model for brain metastases in patients with lung adenocarcinoma.Oncology letters · 2026Article
- Article
- Development of 3D printed capillaric circuit interfacing with silver nanoparticle embedded membrane for simultaneous analysis of duplex samples via fluorescence sandwich immunoassays.Analytical and bioanalytical chemistry · 2026Article
- An EGFR-Targeted Fusogenic Tandem Peptide for siRNA Delivery in Glioblastoma.Pharmaceutics · 2026Article
- On-resin Heck coupling enables small-molecule ligand discovery with covalent peptide-encoded libraries.Chemical science · 2026Article
- Computational Investigation of Cinnamon Phytochemicals Targeting Key Cancer Signaling Pathways: Molecular Docking, ADMET and Molecular Dynamics Simulations Analysis.Current issues in molecular biology · 2026Article
- Multifunctional Nanodiamond Conjugate With a Tumor-Specific EGFR-Targeting Peptide and Photoactivated CO Release for Improved Therapeutic Efficacy in Head and Neck Cancers.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- The effect of transperineal template prostate biopsy (TTPB) on selective serum biomarkers: a clinical-pilot observational study.International urology and nephrology · 2026Observational
- Targeting EGFR Endocytosis and Signaling for Cancer Drug Delivery and Cancer Treatment.Cancers · 2026Review
- Ligand regulation and function of preformed EGFR dimers.Proceedings of the National Academy of Sciences of the United States of America · 2026Article
- Erk inhibitors intercept Erk-mediated negative feedback while imposing cell-cycle arrest and activating p38.iScience · 2026Article
277 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The epidermal growth factor receptor (EGFR) has served as the founding member of the large family of growth factor receptors harboring intrinsic tyrosine kinase function. High abundance of EGFR and large internal deletions are frequently observed in brain tumors, whereas point mutations and small insertions within the kinase domain are common in lung cancer. For these reasons EGFR and its preferred heterodimer partner, HER2/ERBB2, became popular targets of anti-cancer therapies. Nevertheless, EGFR research keeps revealing unexpected observations, which are reviewed herein. Once activated by a ligand, EGFR initiates a time-dependent series of molecular switches comprising downregulation of a large cohort of microRNAs, up-regulation of newly synthesized mRNAs, and covalent protein modifications, collectively controlling phenotype-determining genes. In addition to microRNAs, long non-coding RNAs and circular RNAs play critical roles in EGFR signaling. Along with driver mutations, EGFR drives metastasis in many ways. Paracrine loops comprising tumor and stromal cells enable EGFR to fuel invasion across tissue barriers, survival of clusters of circulating tumor cells, as well as colonization of distant organs. We conclude by listing all clinically approved anti-cancer drugs targeting either EGFR or HER2. Because emergence of drug resistance is nearly inevitable, we discuss the major evasion mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.